Insights
Search Results
Client Highlights
12.08.25
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Client Highlights
6.12.24
Wilson Sonsini Advises Genoa Ventures on Patent Matters Related to AlidaBio’s $7.5 Million Series A
On June 12, 2024, Alida Biosciences (AlidaBio), an innovator in epigenomic research tools, announced it has completed a $7.5 million Series A financing. Genoa Ventures led the funding round with participation from FusionX Ventures and Vertical Venture Partners and is complemented by two ongoing Small Business Innovation Research grants of $4 million from The National Human Genome Research Institute. Wilson Sonsini Goodrich & Rosati advised Genoa Ventures on patent matters related to the transaction.
Client Highlights
11.14.23
Wilson Sonsini Advises CARGO Therapeutics on IP Matters Related to $281 Million IPO
On November 10, 2023, CARGO Therapeutics, a clinical-stage biotech specializing in cancer treatments, made its debut on the Nasdaq Global Select Market under the ticker "CRGX" after successfully raising approximately $281 million through its initial public offering (IPO). The company priced its IPO at $15 per share, issuing 18.75 million shares. Wilson Sonsini Goodrich & Rosati advised CARGO on patent and technology transactions matters leading up to and with respect to the IPO.
Client Highlights
9.25.23
Wilson Sonsini Advises Applied Molecular Transport Inc. in its Sale to Cyclo Therapeutics
On September 21, 2023, Cyclo Therapeutics, Inc., a clinical-stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (AMT), a biopharmaceutical company, announced that the companies have entered into a definitive agreement pursuant to which AMT will merge with Cyclo Therapeutics in an all-stock transaction. Wilson Sonsini Goodrich and Rosati is advising AMT on the transaction.